Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10.09.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 23.07.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19.07.19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19.07.19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19.06.20 |
William McVicar
CHM | Chairman | 66 | 19.07.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Tess Burleson
BRD | Director/Board Member | 57 | 19.07.19 |
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 4 776 433 | 4 486 213 ( 93,92 %) | 0 | 93,92 % |
Unternehmenskontakt
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+25,69 % | 47,9 Mrd. | |
+46,90 % | 41,42 Mrd. | |
-3,46 % | 40,7 Mrd. | |
-6,20 % | 28,92 Mrd. | |
+9,17 % | 25,55 Mrd. | |
-20,42 % | 19,27 Mrd. | |
+0,17 % | 12,15 Mrd. | |
+28,07 % | 12,14 Mrd. | |
-1,24 % | 11,99 Mrd. |